PR Source Quebec City (Quebec, Canada) and Saint Paul (Minnesota, USA), January 16, 2012 – Medicago Inc. (MDG: TSX), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and…

The White House Office of the Press Secretary For Immediate Release December 08, 2011 We Can’t Wait: Obama Administration Announces $2 Billion in Resources to Support Job-Creating Startups Today, the White House announced administrative and private sector actions that will…

Taking another step forward after the failure of a late-stage trial of its lead drug last year, MacroGenics has bagged a pharma deal to fuel development of an immune-stimulating antibody against cancer. Servier, France’s second-largest drugmaker, has ponied up $20 million upfront in the deal that gives it an option to develop and commercialize the drug, dubbed MGA271, for the European market.

PARIS & LA JOLLA, Calif.–(BUSINESS WIRE)–Regulatory News: – Significant scientific advances stemming from the 2008-2011 collaboration – The “Ipsen Life Sciences Program” at the Salk Institute is renewed for a period of 3 years Ipsen (Paris:IPN)(Euronext: IPN; ADR: IPSEY) and…

Source: IPSEN With a strong history of effective and results-oriented partnering, alliance collaboration is a mainstay of how Ipsen operates. As a mid-sized company we are uniquely placed to meet and adapt to the requirements of our partners. In addition…